Lisata Therapeutics announces first patient treated in Phase 2a of LSTA1

Lisata Therapeutics announced treatment of the first patient in a Phase 2a trial evaluating LSTA1 in patients with newly diagnosed glioblastoma multiforme. The trial is an investigator-initiated study by Lenne-Triin Korgvee, MD, PhD, principal investigator of the study. The first patient was enrolled at Tartu University Hospital in Tartu, Estonia. “We are very pleased to announce the first patient treated in this Phase 2a study evaluating LSTA1 in patients with newly diagnosed GBM, a very aggressive brain tumor that is often fatal. We hold great hopes for the benefits of LSTA1 in this indication based on preclinical evidence that demonstrates LSTA1 enhances penetration through the limited permeability of the blood-brain barrier,” stated Kristen Buck, M.D., Executive Vice President of R&D and Chief Medical Officer of Lisata. “We appreciate the efforts of Dr. Korgvee and her team at Tartu University Hospital as well as those patients participating. We look forward to monitoring the results closely.”